US2005266567A1PendingUtilityA1

Methods for generating high titer helper-free preparations of released recombinant AAV vectors

Individually held — no corporate assignee on recordPriority: Sep 5, 1997Filed: Jun 28, 2005Published: Dec 1, 2005
Est. expirySep 5, 2017(expired)· nominal 20-yr term from priority
C07C 2/32C12N 2750/14152C07D 207/34C07F 7/0812C07D 295/30C12N 15/86C07F 9/572C07K 14/005C12N 2750/14143C07D 409/14C07C 2531/22C07F 15/045C12N 2750/14122C07D 401/14A61K 48/0091C07F 9/58C12N 7/00C12N 2750/14151C07D 207/50C07D 207/32
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention provides methods and compositions for producing high titer, substantially purified preparations of recombinant adeno-associated virus (AAV) that can be used as vectors for gene delivery. At the onset of vector production, AAV producer cells of this invention typically comprise one or more AAV packaging genes, an AAV vector comprising a heterologous (i.e. non-AAV) transgene of interest, and a helper virus such as an adenovirus. The AAV vector preparations produced are generally replication incompetent but are capable of mediating delivery of a transgene of interest (such as a therapeutic gene) to any of a wide variety of tissues and cells. The AAV vector preparations produced according to this invention are also substantially free of helper virus as well as helper viral and cellular proteins and other contaminants. The invention described herein provides methods of producing rAAV particles by culturing producer cells under conditions, such as temperature and pH, that promote release of virus. Also provided is a quantitative, high-throughput assay useful in the assessment of viral infectivity and replication, as well as in the screening of agent that affect viral infectivity and/or replication.

Claims

exact text as granted — not AI-modified
1 - 7 . (canceled)  
   
   
       8 . A method of isolating a population of rAAV particles, comprising the steps of: (a) chromatographing an AAV producer cell lysate containing rAAV particles on a positively-charged anion exchange resin; and (b) chromatographing an AAV producer cell lysate containing rAAV particles on a negatively-charged cation exchange resin, whereby a purified population of rAAV particles is generated.  
   
   
       9 - 177 . (canceled)

Join the waitlist — get patent alerts

Track US2005266567A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.